Biodol Therapeutics

Biodol Therapeutics is a French biotechnology company dedicated to developing first-in-class compounds for the treatment of chronic pain. The company focuses on a novel mechanism of action by targeting the Fms-like tyrosine kinase 3 (FLT3) receptor, which has been identified as a key player in the transition from acute to chronic neuropathic pain. Their lead program involves small molecule inhibitors designed to provide long-lasting relief without the side effects associated with current analgesics like opioids. Biodol's research is based on discoveries from the Institute for Functional Genomics (IGF) and the Montpellier Institute for Neurosciences (INM).